Xolair® (omalizumab) resources
Indications:1
Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment.
The recommended dose of Xolair in patients with chronic spontaneous urticaria is 300 mg by subcutaneous injection every four weeks.1
Please refer to the Xolair Summary of Product Characteristics (SmPC) for the full therapeutic indication.1
Tools and promotional resources, created and funded by Novartis, have been designed for healthcare professional to support the use of Xolair in day‑to‑day practice.
If you have any questions please contact your local Novartis key account manager or get in touch using the ‘Contact us’
Explore our range of resources using the tabs below, which have been designed to support you in your management of patients with CSU who are receiving Xolair treatment.
For unbranded CSU PRO forms (UAS7, UCT, DLQI) to download or order, please visit here for details.
Please do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only.
Please note that these resources are designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.
Self-administration initiation checklist
These checklists have been created to help healthcare professionals select and train appropriate CSU patients in their clinic and assess and record their patients’ (or their patients’ carers’) competence to self-administer Xolair.
The materials in this tab are for you to review. If you would like to share them with your patients who have been prescribed Xolair, please direct them to the patient page, where they can view the resources themselves using this link: here
Please note that these resources are designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.
Instruction video for self-injection (pre-filled syringe)
Instruction video for using the Xolair autoinjector
Patients with no known history of anaphylaxis may self-inject Xolair or be injected by a caregiver from the 4th dose onwards if a physician determines that this is appropriate. The patient or the caregiver must have been trained in the correct injection technique and the recognition of the early signs and symptoms of serious allergic reactions.
Patients or caregivers should be instructed to inject the full amount of Xolair according to the instructions provided in the package leaflet.
Learn more about patient-reported outcome measures (UAS7, UCT & DLQI)
CSU, chronic spontaneous urticaria; DLQI, dermatology life quality index; PRO, patient-reported outcome; SmPC, summary of product characteristics; UAS7, urticaria activity score (seven days); UCT, urticaria control test.
Reference
Xolair® (omalizumab) Summary of Product Characteristics.
UK | March 2025 | FA-11360069
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.